1. Omaye ST. Metabolic modulation of carbon monoxide toxicity. Toxicology. 2002; 180:139-150.
2. Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004; 322:1111-1122.
3. Schiltz KL. Failure to assess motivation, need to consider psychiatric variables, and absence of comprehensive examination: a skeptical review of neuropsychologic assessment in carbon monoxide research. Undersea Hyperba Med 2000; 27:48-50.
4. Bell MJ, Kochanek PM, Heyes MP, Wisniewski SR, Sinz EH, Clark RSB, et al. Quinolinic acid in the cerebrospinal fluid of children after traumatic brain injury. Crit Care Med 1999; 27:493-947.
5. Hans P, Born JD, Chapelle JP, Milbouw G. Creatine kinase isoenzymes in severe head injury. J Neurosurg 1983; 58:689-692.
6. Brvar M, Mozina H, Osredkar J, Mozina M, Brucan A, Bunc M. The potential value of the protein S-100B level as a criterion for hyperbaric oxygen treatment and prognostic marker in carbon monoxide poisoned patients. Resuscitation 2003; 56:105-109.
7. Brvar MMD, Finderle aMDP, Suput DMDP, Bunc MMDP. S100B protein in conscious carbon monoxide-poisoned rats treated with normobaric or hyperbaric oxygen. [Report]. (0090-3493).
8. Vos PE, Lamers KJB, Hendriks JCM, Van Haaren M, Beems T, Zimmerman C, et al. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology 2004; 62:1303-1310.
9. Yardan T, Cevik Y, Donderici O, Kavalci C, Yilmaz FM, Yilmaz G, et al. Elevated serum S100B protein and neuron-specific enolase levels in carbon monoxide poisoning. Am J Emerg Med 2009; 27:838-842.
10. Nylén K, Öst M, Csajbok LZ, Nilsson I, Hall C, Blennow K, et al. Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury. Acta Neurochir 2008; 150:221-227.
11. Hergenroeder GW, Redell JB, Moore AN, Dash PK. Biomarkers in the clinical diagnosis and management of traumatic brain injury. Mol Diagn Ther 2008; 12:345-358.
12. Thom SR,Bhopale VM,Fisher D.Hyperbaric oxygen reduces delayed immune-mediated neuropathology in experimental carbon monoxide toxicity. Toxicol Appl Pharmacol 2006; 213:152-159.
13. Ide T, Kamijo Y. Myelin basic protein in cerebrospinal fluid: a predictive marker of delayed encephalopathy from carbon monoxide poisoning.Am J Emerg Med 2008; 26:908-912.
14. Hu M-C, Shiah IS, Yeh C-B, Chen H-K, Chen C-K. Ziprasidone in the treatment of delayed carbon monoxide encephalopathy. Prog Neuro-Psychopharmacol Biol Psychiatry 2006; 30:755-757.
15. Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML, et al. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 2002; 952:128-134.
16. Sattler MB, Merkler D, Maier K, Stadelmann C, Ehrenreich H, Bahr M, et al. Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ 2004; 11:S181-S92.
17. Bloomfield S, McKinney J, Smith L, Brisman J. Reliability of S100B in predicting severity of central nervous system injury. Neurocritical Care 2007; 6:121-138.
18. Gunnarson E, Song Y, Kowalewski JM, Brismar H, Brines M, Cerami A, et al. Erythropoietin modulation of astrocyte water permeability as a component of neuroprotection. Proc Natl Acad Sci USA 2009; 106:1602-1607.
19. Petzold A, Eikelenboom MJ, Gveric D, Keir G, Chapman M, Lazeron RHC, et al. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Brain 2002; 125:1462-1473.
20. Schofield P. Dementia associated with toxic causes and autoimmune disease. Int Psychogeriatr 2005; 17:129-147.
21. Juul S. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr Suppl 2002; 91:36-42.
22. Li Y, Hu X, Lu Z. Erythropoietin in the treatment of encephalopathy associated with carbon monoxide poisoning. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:735-738.